Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus.
Iyer P, Wiles K, Ismail A, Nanda S, Murray K, Hughes S, Ford HL, Pearson OR, White S, Bonham N, Hoyle N, Witts J, Middleton R, Brex PA, Rog D, Dobson R. Iyer P, et al. Among authors: rog d. Mult Scler. 2023 Mar;29(3):395-406. doi: 10.1177/13524585221148094. Epub 2023 Feb 5. Mult Scler. 2023. PMID: 36740816
Olfaction: a review.
Jones N, Rog D. Jones N, et al. Among authors: rog d. J Laryngol Otol. 1998 Jan;112(1):11-24. doi: 10.1017/s0022215100139829. J Laryngol Otol. 1998. PMID: 9538440 Review. No abstract available.
Alemtuzumab and chronic plaque psoriasis.
Aslam A, Marsland AM, Rog D, Griffiths CE. Aslam A, et al. Among authors: rog d. Br J Dermatol. 2013 Jul;169(1):184-6. doi: 10.1111/bjd.12226. Br J Dermatol. 2013. PMID: 23834118 No abstract available.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Confavreux C, et al. Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461574 Clinical Trial.
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA. McGuigan C, et al. Among authors: rog d. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):117-25. doi: 10.1136/jnnp-2015-311100. Epub 2015 Oct 22. J Neurol Neurosurg Psychiatry. 2016. PMID: 26492930 Free PMC article. Review.
Validating the portal population of the United Kingdom Multiple Sclerosis Register.
Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, Noble DG, Jones KH, Al-Din A, Craner M, Evangelou N, Harman P, Harrower T, Hobart J, Husseyin H, Kasti M, Kipps C, McDonnell G, Owen C, Pearson O, Rashid W, Wilson H, Ford DV. Middleton RM, et al. Among authors: rog d. Mult Scler Relat Disord. 2018 Aug;24:3-10. doi: 10.1016/j.msard.2018.05.015. Epub 2018 May 25. Mult Scler Relat Disord. 2018. PMID: 29860199
93 results